Weekly Digest – August 2024 Weekly Digest – August 2024 28 Aug 2024: China’s Duality Biotherapeutics Seeks IPO to Accelerate ADC Development Duality Biotherapeutics, a clinical-stage biotech company in China, has filed for an IPO on the Hong Kong Stock […]
Weekly Digest – August 2024 Weekly Digest – August 2024 27 Aug 2024: Mabwell receives approval for Phase III trial of urothelial carcinoma drug in China Mabwell Therapeutics has received approval from NMPA to begin a Phase III clinical trial […]
Weekly Digest – August 2024 Weekly Digest – August 2024 27 Aug 2024: LigaChem collaborates with CStone on LCB71, showing efficacy in solid tumors and hematological cancers in global Phase 1 clinical trial LigaChem Biosciences reported that its ROR1 ADC […]
Monthly Digest – August 2024 Monthly Digest – August 2024 28 Aug 2024: Enfortumab vedotin plus pembrolizumab approved in Europe for urothelial carcinoma The European Commission (EC) has approved the combination of enfortumab vedotin-ejfv (EV, Padcev) and pembrolizumab (Keytruda) for […]
